Comparison of in vitro activity of cefepime against fresh clinical isolates and isolates 10 years ago

R. Okamoto, R. Nakano, Y. Hosaka, T. Hara, A. Miyata, Y. Hirata, Y. Shimizu, S. Kinoshita, K. Kajinura, Nobuchika Kusano, A. Saitoh, M. Inoue

Research output: Contribution to journalArticle

Abstract

The antibacterial activity of cefepime, cefozopran, cefpirome, ceftazidime, cefotaxime, piperacillin, and imipenem/cilastatin against clinical isolates in 1996-98 were tested (a total of 523 strains from 19 organism groups, i.e., methicillin-susceptible Staphylococcus aureus and Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, Moraxella (Branhamella) catarrhalis, Citrobacter freundii, Enterobacter cloacae, Enterobacter aerogenes, Proteus mirabilis, Proteus vulgaris, Morganella morganii, Serratia marcescens, Pseudomonas aeruginosa, Burkholderia cepacia, Acinetobacter spp. and Bacteroides spp.) and compared to those against clinical isolates in 1985-87, prior to cefepime use. Staphylococci were uniformly susceptible (MIC90, ≤0.025 3.13 μg/mL) to all drugs except ceftazidime (MIC90, 12.5 μg/mL). This did not change in 1985-87. Among E. coli and K. pneumoniae, the ranking of antibacterial activity was cefepime > cefpirome= cefozopran>imipenem/cilastatin>ceftazidime>piperacillin. Isolates of 13.3% of C. freundii and 16.7% of E. cloacae resistant to ceftazidime (13.3, 16.7% resistance respectibility) remained susceptible to cefepime and imipenem/cilastatin. Imipenem and fourth-generation cephalosporin were stable to β-lactamase produced from these species. P. aeruginosa isolates were susceptible to cefepime, cefozopran, ceftazidime and imipenem/cilastatin. Metalloenzyme was identified in I strain of S. marcescense. No difference in the antibacterial activity of cefepime to most species of bacteria was seen between this study and that 10 years ago. Cefepime thus has a low rate of selection in drug resistance because it has potent antibacterial activity and is stable to β-lactamase. Our results suggest that cefepime is useful in the treatment of bacterial infections. An extended-spectrum β-lactamase was identified in 2 strains from 82 E. coli strains isolated from the same clinical center and showed the same pulsed-field gel electrophoresis (PFGE) pattern. It was surmised that the same clone had spread throughout the hospital.

Original languageEnglish
Pages (from-to)719-731
Number of pages13
JournalJapanese Journal of Chemotherapy
Volume48
Issue number9
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

Ceftazidime
cefpirome
Citrobacter freundii
Enterobacter cloacae
Piperacillin
Klebsiella pneumoniae
Escherichia coli
Pseudomonas aeruginosa
Morganella morganii
Proteus vulgaris
Enterobacter aerogenes
Burkholderia cepacia
Moraxella (Branhamella) catarrhalis
Proteus mirabilis
Serratia marcescens
Bacteroides
Acinetobacter
Methicillin
Staphylococcus epidermidis
Cefotaxime

Keywords

  • Cefepime
  • Class C
  • ESBLs

ASJC Scopus subject areas

  • Pharmacology

Cite this

Okamoto, R., Nakano, R., Hosaka, Y., Hara, T., Miyata, A., Hirata, Y., ... Inoue, M. (2000). Comparison of in vitro activity of cefepime against fresh clinical isolates and isolates 10 years ago. Japanese Journal of Chemotherapy, 48(9), 719-731.

Comparison of in vitro activity of cefepime against fresh clinical isolates and isolates 10 years ago. / Okamoto, R.; Nakano, R.; Hosaka, Y.; Hara, T.; Miyata, A.; Hirata, Y.; Shimizu, Y.; Kinoshita, S.; Kajinura, K.; Kusano, Nobuchika; Saitoh, A.; Inoue, M.

In: Japanese Journal of Chemotherapy, Vol. 48, No. 9, 2000, p. 719-731.

Research output: Contribution to journalArticle

Okamoto, R, Nakano, R, Hosaka, Y, Hara, T, Miyata, A, Hirata, Y, Shimizu, Y, Kinoshita, S, Kajinura, K, Kusano, N, Saitoh, A & Inoue, M 2000, 'Comparison of in vitro activity of cefepime against fresh clinical isolates and isolates 10 years ago', Japanese Journal of Chemotherapy, vol. 48, no. 9, pp. 719-731.
Okamoto, R. ; Nakano, R. ; Hosaka, Y. ; Hara, T. ; Miyata, A. ; Hirata, Y. ; Shimizu, Y. ; Kinoshita, S. ; Kajinura, K. ; Kusano, Nobuchika ; Saitoh, A. ; Inoue, M. / Comparison of in vitro activity of cefepime against fresh clinical isolates and isolates 10 years ago. In: Japanese Journal of Chemotherapy. 2000 ; Vol. 48, No. 9. pp. 719-731.
@article{2c914383970b46a0ad4b50e47fedd046,
title = "Comparison of in vitro activity of cefepime against fresh clinical isolates and isolates 10 years ago",
abstract = "The antibacterial activity of cefepime, cefozopran, cefpirome, ceftazidime, cefotaxime, piperacillin, and imipenem/cilastatin against clinical isolates in 1996-98 were tested (a total of 523 strains from 19 organism groups, i.e., methicillin-susceptible Staphylococcus aureus and Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, Moraxella (Branhamella) catarrhalis, Citrobacter freundii, Enterobacter cloacae, Enterobacter aerogenes, Proteus mirabilis, Proteus vulgaris, Morganella morganii, Serratia marcescens, Pseudomonas aeruginosa, Burkholderia cepacia, Acinetobacter spp. and Bacteroides spp.) and compared to those against clinical isolates in 1985-87, prior to cefepime use. Staphylococci were uniformly susceptible (MIC90, ≤0.025 3.13 μg/mL) to all drugs except ceftazidime (MIC90, 12.5 μg/mL). This did not change in 1985-87. Among E. coli and K. pneumoniae, the ranking of antibacterial activity was cefepime > cefpirome= cefozopran>imipenem/cilastatin>ceftazidime>piperacillin. Isolates of 13.3{\%} of C. freundii and 16.7{\%} of E. cloacae resistant to ceftazidime (13.3, 16.7{\%} resistance respectibility) remained susceptible to cefepime and imipenem/cilastatin. Imipenem and fourth-generation cephalosporin were stable to β-lactamase produced from these species. P. aeruginosa isolates were susceptible to cefepime, cefozopran, ceftazidime and imipenem/cilastatin. Metalloenzyme was identified in I strain of S. marcescense. No difference in the antibacterial activity of cefepime to most species of bacteria was seen between this study and that 10 years ago. Cefepime thus has a low rate of selection in drug resistance because it has potent antibacterial activity and is stable to β-lactamase. Our results suggest that cefepime is useful in the treatment of bacterial infections. An extended-spectrum β-lactamase was identified in 2 strains from 82 E. coli strains isolated from the same clinical center and showed the same pulsed-field gel electrophoresis (PFGE) pattern. It was surmised that the same clone had spread throughout the hospital.",
keywords = "Cefepime, Class C, ESBLs",
author = "R. Okamoto and R. Nakano and Y. Hosaka and T. Hara and A. Miyata and Y. Hirata and Y. Shimizu and S. Kinoshita and K. Kajinura and Nobuchika Kusano and A. Saitoh and M. Inoue",
year = "2000",
language = "English",
volume = "48",
pages = "719--731",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "9",

}

TY - JOUR

T1 - Comparison of in vitro activity of cefepime against fresh clinical isolates and isolates 10 years ago

AU - Okamoto, R.

AU - Nakano, R.

AU - Hosaka, Y.

AU - Hara, T.

AU - Miyata, A.

AU - Hirata, Y.

AU - Shimizu, Y.

AU - Kinoshita, S.

AU - Kajinura, K.

AU - Kusano, Nobuchika

AU - Saitoh, A.

AU - Inoue, M.

PY - 2000

Y1 - 2000

N2 - The antibacterial activity of cefepime, cefozopran, cefpirome, ceftazidime, cefotaxime, piperacillin, and imipenem/cilastatin against clinical isolates in 1996-98 were tested (a total of 523 strains from 19 organism groups, i.e., methicillin-susceptible Staphylococcus aureus and Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, Moraxella (Branhamella) catarrhalis, Citrobacter freundii, Enterobacter cloacae, Enterobacter aerogenes, Proteus mirabilis, Proteus vulgaris, Morganella morganii, Serratia marcescens, Pseudomonas aeruginosa, Burkholderia cepacia, Acinetobacter spp. and Bacteroides spp.) and compared to those against clinical isolates in 1985-87, prior to cefepime use. Staphylococci were uniformly susceptible (MIC90, ≤0.025 3.13 μg/mL) to all drugs except ceftazidime (MIC90, 12.5 μg/mL). This did not change in 1985-87. Among E. coli and K. pneumoniae, the ranking of antibacterial activity was cefepime > cefpirome= cefozopran>imipenem/cilastatin>ceftazidime>piperacillin. Isolates of 13.3% of C. freundii and 16.7% of E. cloacae resistant to ceftazidime (13.3, 16.7% resistance respectibility) remained susceptible to cefepime and imipenem/cilastatin. Imipenem and fourth-generation cephalosporin were stable to β-lactamase produced from these species. P. aeruginosa isolates were susceptible to cefepime, cefozopran, ceftazidime and imipenem/cilastatin. Metalloenzyme was identified in I strain of S. marcescense. No difference in the antibacterial activity of cefepime to most species of bacteria was seen between this study and that 10 years ago. Cefepime thus has a low rate of selection in drug resistance because it has potent antibacterial activity and is stable to β-lactamase. Our results suggest that cefepime is useful in the treatment of bacterial infections. An extended-spectrum β-lactamase was identified in 2 strains from 82 E. coli strains isolated from the same clinical center and showed the same pulsed-field gel electrophoresis (PFGE) pattern. It was surmised that the same clone had spread throughout the hospital.

AB - The antibacterial activity of cefepime, cefozopran, cefpirome, ceftazidime, cefotaxime, piperacillin, and imipenem/cilastatin against clinical isolates in 1996-98 were tested (a total of 523 strains from 19 organism groups, i.e., methicillin-susceptible Staphylococcus aureus and Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, Moraxella (Branhamella) catarrhalis, Citrobacter freundii, Enterobacter cloacae, Enterobacter aerogenes, Proteus mirabilis, Proteus vulgaris, Morganella morganii, Serratia marcescens, Pseudomonas aeruginosa, Burkholderia cepacia, Acinetobacter spp. and Bacteroides spp.) and compared to those against clinical isolates in 1985-87, prior to cefepime use. Staphylococci were uniformly susceptible (MIC90, ≤0.025 3.13 μg/mL) to all drugs except ceftazidime (MIC90, 12.5 μg/mL). This did not change in 1985-87. Among E. coli and K. pneumoniae, the ranking of antibacterial activity was cefepime > cefpirome= cefozopran>imipenem/cilastatin>ceftazidime>piperacillin. Isolates of 13.3% of C. freundii and 16.7% of E. cloacae resistant to ceftazidime (13.3, 16.7% resistance respectibility) remained susceptible to cefepime and imipenem/cilastatin. Imipenem and fourth-generation cephalosporin were stable to β-lactamase produced from these species. P. aeruginosa isolates were susceptible to cefepime, cefozopran, ceftazidime and imipenem/cilastatin. Metalloenzyme was identified in I strain of S. marcescense. No difference in the antibacterial activity of cefepime to most species of bacteria was seen between this study and that 10 years ago. Cefepime thus has a low rate of selection in drug resistance because it has potent antibacterial activity and is stable to β-lactamase. Our results suggest that cefepime is useful in the treatment of bacterial infections. An extended-spectrum β-lactamase was identified in 2 strains from 82 E. coli strains isolated from the same clinical center and showed the same pulsed-field gel electrophoresis (PFGE) pattern. It was surmised that the same clone had spread throughout the hospital.

KW - Cefepime

KW - Class C

KW - ESBLs

UR - http://www.scopus.com/inward/record.url?scp=0033769869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033769869&partnerID=8YFLogxK

M3 - Article

VL - 48

SP - 719

EP - 731

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - 9

ER -